Jean-Paul Becker

Dr. Jean-Paul Becker

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LBLaurie Bibens
Laurie Bibens
JBJean-Paul Becker
Jean-Paul Becker
Alexandra Dassonville-KlimptAlexandra Dassonville-Klimpt
Alexandra Dassonville-Klimpt
Pascal SonnetPascal Sonnet
Pascal Sonnet
Resistance to antimicrobial drugs is currently a serious threat to human health. Consequently, we are facing an urgent need for new antimicrobial drugs acting with original modes of action. The ubiquitous and widely conserved microbial fatty acid biosynthesis pathway, called FAS-II system, represents a potential target to tackle antimicrobial resistance. This pathway has been extensively studied, and eleven proteins have been described. FabI (or InhA, its homologue in mycobacteria) was considered as a prime target by many teams and is currently the only enzyme with commercial inhibitor drugs: triclosan and isoniazid. Furthermore, afabicin and CG400549, two promising compounds which also target FabI, are in clinical assays to treat Staphylococcus aureus. However, most of the other enzymes are still underexploited targets. This review, after presenting the FAS-II system and its enzymes in Escherichia coli, highlights the reported inhibitors of the system. Their biological activities, main interactions formed with their targets and structure–activity relationships are presented as far as possible.

19 July 2024 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
MHMarie Hanot
Marie Hanot
MDMarine Duplantier
Marine Duplantier
CDCeline Dalle
Celine Dalle
YRYani Ren
Yani Ren
SNSophie Da Nascimento
Sophie Da Nascimento
Pascal SonnetPascal Sonnet
Pascal Sonnet
Antibiotic resistance is a critical public health issue. Among the multi-drug resistant microorganisms in question, Pseudomonas aeruginosa has been designated by the WHO as a priority threat. Its virulence is orchestrated through quorum sensing (QS). This sophisticated communication network relies on the release and perception of autoinducers acting as population density indicators. Therefore, the interest of a quorum silencing pharmacological approach has unfolded to quench bacterial pathogenicity without impairing growth. In this article, we reported the development of a family of indazole–quinolone hybrids as anti-virulence agents. These new biaromatic compounds were designed as potential specific QS quenchers against P. aeruginosa. Our transdisciplinary research methodology included their synthesis using palladocatalyzed cross-coupling reactions, as well as their in silico physicochemical and in vitro biological evaluation. The hit 7-chloro-2-indazolyl-4-quinolone Ie shows a promising anti-biofilm and anti-pyocyanin efficiency (35% inhibition at 25 µM and 35% inhibition at 100 µM, respectively) without an anti-pseudomonal bacteriostatic effect. It also demonstrated a moderate eukaryotic cytotoxicity. Its anti-QS properties have been investigated using metabolomic and molecular modelling studies.

18 June 2017
Verified
Book Chapter
Closed access
PDF file
EOElena Ochoa-Chaidez
Elena Ochoa-Chaidez
EGElvia L. Gonzalez-Muñoz
Elvia L. Gonzalez-Muñoz
EHEnrique Herrera-Lugo
Enrique Herrera-Lugo
JBJean-Paul Becker
Jean-Paul Becker

1 November 2022 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
LBLaurie Bibens
Laurie Bibens
JBJean-Paul Becker
Jean-Paul Becker
NLNadine Lemaître
Nadine Lemaître
FPFrançois Peltier
François Peltier
VMVirginie Morel
Virginie Morel
Pascal SonnetPascal Sonnet
Pascal Sonnet
At present, antimicrobial resistance is one of the most significant public health challenges